Focused On-demand Library for Oxidoreductase HTATIP2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BUP3

UPID:

HTAI2_HUMAN

Alternative names:

30 kDa HIV-1 TAT-interacting protein; HIV-1 TAT-interactive protein 2

Alternative UPACC:

Q9BUP3; A8K7S7; D3DQY8; O15383; O60520; O95345; Q53GC1; Q53GG2; Q6IBI3

Background:

Oxidoreductase HTATIP2, also known as 30 kDa HIV-1 TAT-interacting protein and HIV-1 TAT-interactive protein 2, plays a crucial role in tumor suppression. Its activity involves the inhibition of nuclear import by competing with substrates for binding to nuclear transport receptors, potentially acting as a redox sensor that regulates transcription through nuclear import control. Isoform 1 is noted for its metastasis suppression, proapoptotic, and antiangiogenic properties, while Isoform 2 exhibits an antiapoptotic effect.

Therapeutic significance:

Understanding the role of Oxidoreductase HTATIP2 could open doors to potential therapeutic strategies.